Guided Therapeutics Receives Order for 10 LuViva® Advanced Cervical Scans for Indonesia

Get Instant Instagram Followers and Likes with GetInsta

GetInsta App is 100% safe and secure to get benefits from online smart feature plans. There are lots of reliable and smart feature explorations to achieve your objectives. Learn more!

Philips Introduces Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.

Lawson Health Research Institute Found Simple Device Improves Care After Kidney Transplantation

The geko™ device, manufactured by Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solutions Inc., is a muscle pump activator that significantly improves blood flow by stimulating the body’s ‘muscle pumps.’

Technology gaining momentum in 4th largest market

Guided Therapeutics, Inc. (OTCQB: GTHP), developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced it has received an order for 10 additional LuViva® Advanced Cervical Scans for Indonesia.

The order brings to 24 the number of LuVivas and more than 7,000 the number of single use Cervical Guides sold to Indonesia. Additional orders of Cervical Guides are expected later this year.

LuViva has been recommended as an alternative to the Pap test by doctors presenting at the 22nd Annual Scientific Meeting of the Society of Obstetricians and Gynecologists of Indonesia.

“Indonesia is an important market for LuViva where it has demonstrated its value as an alternative to lab–based testing with the benefits of an immediate result and no painful tissue sample,” said Gene Cartwright, CEO and President of Guided Therapeutics, Inc. “In areas were the laboratory infrastructure is limited, LuViva presents a tremendous improvement in women’s access to healthcare.”

Cervical cancer is the second most common malignancy among women of Indonesia with an incidence rate of about 17 in 100,000. In Indonesia, where 70% of cervical cancer cases diagnosed are in an advanced stage, there is a clear unmet need to increase screening to detect cervical disease before it develops into cancer.

In Indonesia, more than 93 million women are at risk of developing cervical cancer. Less than 25% of women aged 30 to 50 are screened for cervical cancer in Indonesia with the primary method of visual inspection with acetic acid.

There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.



Subscribe to Medical Device News Magazine here.

Related Articles